Extract

Objective

Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by urological guidelines. However, some patients do not respond to drug therapies. Platelet-rich plasma (PRP) has been suggested to be effective in the management of ED. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) for the treatment of ED.

Methods

60 patients aged 43.7 (SD=13.7) with ED (mean duration of ED was 7.7±1.7 months) were randomly separated into 2 groups. Group A received 4 ml activated PRP (aPRP) intracavernosal injection weekly (totally 3 times), while Group B received PRP injections according to the same schedule plus 5 mg of tadalafil daily during 28 days. The International Index of Erectile Function (IIEF), Erection Hardness Scale (EHS), EndoPAT, Penile duplex Doppler ultrasound (PDDU), Sexual Encounter Profile (SEP) and complications (if any) were evaluated at 4 weeks, 3 and 6 months. Data sets were statistically compared and p<0.05 was considered as significant.

You do not currently have access to this article.